IPCA Unveils Diulcus Gel: A Breakthrough For Diabetic Foot Ulcers | Health Live

In a recent press conference held at the Press Club of India, IPCA Laboratories introduced a groundbreaking new drug, Diulcus, for treating diabetic foot ulcers. The discussion highlighted the severe impact of diabetes, with approximately 27% of India's population affected, including 10 crore diabetics and 13.6 crore pre-diabetics. Foot ulcers, a serious complication, affect 25-40% of diabetic patients, often leading to amputations. Diulcus has shown promising results in clinical trials, with over 60% of ulcers healing within two months and 77% of patients maintaining improvement even after treatment cessation. This new drug, developed by Nowa Lead Pharma and globally patented, represents a significant advancement in diabetic foot ulcer treatment, addressing a major unmet medical need.